Author:
Martinez Rebeca,Mayur Omkar,McGee Jean S.
Publisher
Springer Science and Business Media LLC
Reference5 articles.
1. Binus AM, Qureshi AA, Li VW, Winterfield LS (2011) Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities and therapy in 103 patients. Br J Dermatol 165(6):1244–1250
2. Di Xia F, Liu K, Lockwood S, Butler D, Tsiaras WG, Joyce C, Mostaghimi A (2018) Risk of developing pyoderma gangrenosum after procedures in patients with a known history of pyoderma gangrenosum—a retrospective analysis. J Am Acad Dermatol 78(2):310–314
3. Lee S, Lee JY, Ju HJ, Lee JH, Koh SB, Bae JM, Han JH (2023) Association of all-cause and cause-specific mortality risks with pyoderma gangrenosum. JAMA Dermatology 159(2):151–159
4. Barbosa NS, Tolkachjov SN, El-Azhary RA, Davis MD, Camilleri MJ, McEvoy MT, Wetter DA (2016) Clinical features, causes, treatments, and outcomes of peristomal pyoderma gangrenosum (PPG) in 44 patients: the Mayo Clinic experience, 1996 through 2013. J Am Acad Dermatol 75(5):931–939
5. Mayur O, Martinez R, McGee JS (in press) Clinical features, treatments, and therapeutic outcomes of peristomal versus non-peristomal pyoderma gangrenosum in 45 patients with inflammatory bowel disease: a single institution experience, 2002 through 2021. Skinmed